This phase 3 clinical trial was called Intercept, the second phase 3 clinical trial completed after the Momentum phase 3 trial for patients experiencing an acute migraine. Below are the highlights of the successful trial, and the Intercept Phase 3.
- Pain Freedom 2 hours after dosing achieved by 32.6% of patients
- Pain Freedom at 24 hours after dosing in 22.7% of patients
- Freedom from most bothersome symptoms achieved in 43.9% of patients
- Rescue medication was used by 15.3% of patients at 24 hours
Based on these results, I expect the company to prepare and file an NDA (new drug application) prior to year end. Thank you for reading.
No comments:
Post a Comment